Viralytics CEO, biotech veteran join company board
09 September, 2014 by Dylan Bushell-EmblingFormer CSL (ASX:CSL) executive Peter Turvey has been named a Viralytics (ASX:VLA) non-executive director, while Viralytics CEO Malcolm McColl will take the role of managing director.
ResMed settles dispute with APEX Medical
06 September, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has declared a truce in its copyright infringement war with Taiwan's APEX Medical, signing a confidential settlement.
Antisense's ATL1103 shows promise in acromegaly
05 September, 2014 by Dylan Bushell-EmblingAntisense Therapeutics' (ASX:ANP) ATL1103 candidate reduced sIGF-I levels in patients with the growth disorder acromegaly during a phase II trial.
Action urged to capitalise on opportunity as Budget tables reveal loss of support
04 September, 2014The release of the federal government's Science, Research and Innovation Budget Tables this week reveals the losses of almost $400m to science, research and innovation, prompting AusBiotech to reinforce its calls for urgent and specific action that will drive growth in the biotechnology industry and, therefore, the Australian economy.
GSK to shut down Medicines Research Unit
04 September, 2014 by Dylan Bushell-EmblingGSK will cease operation of its research unit at Sydney's Prince of Wales Hospital at the end of the month, laying off eight employees and five contractors.
Pharmaxis to take anti-inflammatory to human trials
03 September, 2014 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) plans to conduct the first human trials of PXS4728A - a drug candidate for inflammatory diseases including COPD and NASH - in 1Q15.
PAP therapy saves lives in heart patients: ResMed
02 September, 2014 by Dylan Bushell-EmblingPositive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce mortality rates by up to 38%, analysis from ResMed (ASX:RMD) suggests.
Australia's medical research sector advocates for the Medical Research Future Fund
02 September, 2014The newly formed Medical Research Future Fund (MRFF) Action Group is advocating for what it claims to be the most important initiative in Australian medical research in generations.
GI Dynamics lines up new CEO
01 September, 2014 by Dylan Bushell-EmblingSeasoned medical device executive Michael Dale will take over from Stuart A Randle as CEO of GI Dynamics (ASX:GID) from next month.
Phylogica awarded three new peptide patents
29 August, 2014 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has added a Japanese patent and two more from the US to its intellectual property portfolio.
AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive
28 August, 2014AusBiotech fully supports the Australian Greens' moving of an amendment in the Senate to put in place quarterly payments for small and medium-size businesses eligible for an R&D Tax Incentive refund.
AFL approves use of Regeneus's HiQCell
28 August, 2014 by Dylan Bushell-EmblingThe AFL has added Regeneus (ASX:RGS) HiQCell to a list of approved treatments for injuries including impact-related osteoarthritis and tendonitis.
Mesoblast posts wider loss, details product roadmap
27 August, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has announced its financial results for FY14 and laid out a five-pronged strategy for commercialising its key regenerative medicine products.
Vaxxas recognised by WEF for vaccine tech
27 August, 2014 by Dylan Bushell-EmblingVaxxas has been selected as a 2015 Technology Pioneer by the World Economic Forum for its patch-based vaccine delivery technology.
ResMed scores initial win in ITC case against BMC
26 August, 2014 by Dylan Bushell-EmblingA US ITC judge has found in favour of ResMed (ASX:RMD) in the company's patent infringement action against China's BMC Medical, and has recommended an import ban.
